AI Summary
We reviewed 82 live results for steqeyma (ustekinumab biosimilar) and narrowed them down to the 3 options that look most worth comparing first.
The strongest themes across this short list are Pharmaceuticals and Biosimilars.
Comparison Table
Recommended
Steqeyma (ustekinumab biosimilar)
Source: Celltrion Healthcare
Description
Steqeyma is a biosimilar version of ustekinumab that has received approval from the Singapore Health Sciences Authority (HSA). It is indicated for treating inflammatory conditions such as plaque psoriasis and Crohn's disease, and is slated for subsidy under the Ministry of Health's Standard Drug List (SDL).
Best for
subsidized drug seekers in Singapore, long-term inflammatory care and HSA-approved biosimilar users
View Details
Rating
Epyztek (ustekinumab)
Source: Samsung Bioepis
Description
Epyztek is the South Korean market brand for the ustekinumab biosimilar developed by Samsung Bioepis. Indicated for patients with psoriasis and other autoimmune conditions, it provides a high-quality local alternative to the originator product, Stelara.
Best for
patients in South Korea, psoriasis treatment and local biosimilar seekers
View Details
Rating
BAT2206 (Ustekinumab)
Source: Dr. Reddy’s Laboratories
Description
BAT2206 is a biosimilar candidate for Ustekinumab, targeting autoimmune conditions like plaque psoriasis and psoriatic arthritis.
Best for
plaque psoriasis, psoriatic arthritis and autoimmune disease treatment
View Details
Rating
| Compare | Steqeyma (ustekinumab biosimilar) | Epyztek (ustekinumab) | BAT2206 (Ustekinumab) |
|---|---|---|---|
| Source | Celltrion Healthcare | Samsung Bioepis | Dr. Reddy’s Laboratories |
| Description | Steqeyma is a biosimilar version of ustekinumab that has received approval from the Singapore Health Sciences Authority (HSA). It is indicated for treating inflammatory conditions such as plaque psoriasis and Crohn's disease, and is slated for subsidy under the Ministry of Health's Standard Drug List (SDL). | Epyztek is the South Korean market brand for the ustekinumab biosimilar developed by Samsung Bioepis. Indicated for patients with psoriasis and other autoimmune conditions, it provides a high-quality local alternative to the originator product, Stelara. | BAT2206 is a biosimilar candidate for Ustekinumab, targeting autoimmune conditions like plaque psoriasis and psoriatic arthritis. |
| Best for | subsidized drug seekers in Singapore, long-term inflammatory care and HSA-approved biosimilar users | patients in South Korea, psoriasis treatment and local biosimilar seekers | plaque psoriasis, psoriatic arthritis and autoimmune disease treatment |
| Tags | |||
| Action | View Details | View Details | View Details |
| Rating |
AI Recommendation
If you want the most balanced option to start with, I recommend:
"Steqeyma (ustekinumab biosimilar) from Celltrion Healthcare."
I picked this because Steqeyma is a recently HSA-approved biosimilar in Singapore that will soon offer enhanced affordability through government drug subsidies.
Share this search
Related Finds